Drugs / DXC014
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07177937 | Mar 2026 → Oct 2030 expected | melanoma, prostate cancer, small cell lung carcinoma | Hangzhou DAC Biotechnology Co., Ltd. | Recruiting | No outcome recorded |
Evidence & citations 1 cited value
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | DXC014 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07177937 ↗ |